|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5580756A
(en)
|
1990-03-26 |
1996-12-03 |
Bristol-Myers Squibb Co. |
B7Ig fusion protein
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
WO1992019266A1
(en)
|
1991-05-06 |
1992-11-12 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
ES2091684T3
(es)
|
1992-11-13 |
1996-11-01 |
Idec Pharma Corp |
Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US6361770B1
(en)
|
1994-09-23 |
2002-03-26 |
University Of British Columbia |
Method of enhancing expression of MHC class I molecules bearing endogenous peptides
|
|
JP3907698B2
(ja)
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
US6632670B1
(en)
|
1995-09-08 |
2003-10-14 |
Genzyme Corporation |
AAV vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
AU8828598A
(en)
|
1997-08-15 |
1999-03-08 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
DE60039766D1
(de)
|
1999-08-09 |
2008-09-18 |
Targeted Genetics Corp |
Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
ATE366814T1
(de)
|
1999-09-21 |
2007-08-15 |
Genetics Inst Llc |
Gl50 moleküle, sowie verwendungen derselben
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
WO2001045737A2
(en)
|
1999-12-22 |
2001-06-28 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
KR100802403B1
(ko)
|
2000-01-21 |
2008-02-13 |
바이오벡스 리미티드 |
바이러스 주
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
JP2004513878A
(ja)
|
2000-06-23 |
2004-05-13 |
マキシジェン， インコーポレイテッド |
新規同時刺激分子
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
JP2004501624A
(ja)
|
2000-06-28 |
2004-01-22 |
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー |
Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
DE60239394D1
(de)
|
2001-05-11 |
2011-04-21 |
Wellstat Biologics Corp |
Onkolytische virustherapie
|
|
EP1406653A4
(en)
|
2001-06-29 |
2005-05-04 |
Univ Leland Stanford Junior |
T CELL REGULATION GENES AND METHOD OF USE THEREOF
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
AU2002352913B2
(en)
|
2001-11-30 |
2008-05-29 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen, and uses therefor
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
AU2003258060B2
(en)
|
2002-03-27 |
2007-07-12 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US8535672B2
(en)
|
2002-04-04 |
2013-09-17 |
Yissum Research Development Of The Hebrew University Of Jerusalem |
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
RU2314830C2
(ru)
|
2002-06-21 |
2008-01-20 |
Веллстат Байолоджикс Корпорейшн |
Введение терапевтических вирусов
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
CN1820078A
(zh)
|
2002-09-09 |
2006-08-16 |
田纳西大学研究基金会 |
弹状病毒的重组突变体及其应用方法
|
|
CN1720060B
(zh)
|
2002-10-03 |
2011-12-14 |
惠氏控股公司 |
人乳头瘤病毒多肽和免疫原性组合物
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
EP1606411B1
(en)
|
2003-03-27 |
2008-12-10 |
Ottawa Health Research Institute |
Mutant vesicular stomatitis viruses and use thereof
|
|
SG179291A1
(en)
|
2003-06-18 |
2012-04-27 |
Genelux Corp |
Modified recombinant vaccinia viruses and other microorganisms, uses thereof
|
|
EP2298926A1
(en)
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
JP2007511216A
(ja)
|
2003-11-17 |
2007-05-10 |
クルセイド ラボラトリーズ リミテッド |
変異ウイルス
|
|
WO2005063816A2
(en)
|
2003-12-19 |
2005-07-14 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
US8986672B2
(en)
|
2005-06-23 |
2015-03-24 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
CA2854576A1
(en)
|
2005-07-18 |
2007-01-25 |
Haichun Huang |
Human anti-b7rp1 neutralizing antibodies
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
SG173337A1
(en)
|
2006-07-21 |
2011-08-29 |
California Inst Of Techn |
Targeted gene delivery for dendritic cell vaccination
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
AU2007331672A1
(en)
|
2006-12-15 |
2008-06-19 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
GB2446721B
(en)
|
2007-02-16 |
2009-03-25 |
Crusade Lab Ltd |
Herpes simplex viruses and methods of viral replication
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
EP2514762B1
(en)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC variants
|
|
CA2693623A1
(en)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
WO2009067800A1
(en)
|
2007-11-27 |
2009-06-04 |
Viventia Biotech Inc. |
Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof
|
|
RS56844B1
(sr)
|
2007-12-11 |
2018-04-30 |
Univ North Carolina Chapel Hill |
Retrovirusni vektori sa modifikovanim polipurinskim nizom
|
|
EP2250278B1
(en)
|
2008-02-21 |
2023-04-05 |
Burnham Institute for Medical Research |
Methods and compositions related to peptides and proteins with c-terminal elements
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
EP2300023A2
(en)
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
CA2735006A1
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
WO2010059253A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
WO2011011584A1
(en)
|
2009-07-24 |
2011-01-27 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
|
JP5883384B2
(ja)
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
|
CA2775761C
(en)
|
2009-09-30 |
2018-08-28 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US9133436B2
(en)
|
2010-02-04 |
2015-09-15 |
The Trustees Of The University Of Pennsylvania |
ICOS critically regulates the expansion and function of inflammatory human Th17 cells
|
|
WO2011113019A2
(en)
|
2010-03-12 |
2011-09-15 |
Abbott Biotherapeutics Corp. |
Ctla4 proteins and their uses
|
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
|
US9029315B2
(en)
|
2010-11-11 |
2015-05-12 |
The University Of Hong Kong |
Soluble PD-1 variants, fusion constructs, and uses thereof
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
MX348071B
(es)
|
2011-03-16 |
2017-05-26 |
Amgen Inc |
Variantes de fc.
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
CN102836441B
(zh)
|
2011-06-24 |
2019-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
EP2726101B1
(en)
|
2011-06-30 |
2018-08-08 |
Genzyme Corporation |
Inhibitors of t-cell activation
|
|
EP2726503B1
(en)
*
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
CN107496932A
(zh)
|
2012-02-27 |
2017-12-22 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
EP2831095B1
(en)
|
2012-03-30 |
2018-11-28 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
|
|
WO2013156054A1
(en)
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
|
SG10201609447XA
(en)
|
2012-05-11 |
2017-01-27 |
Medimmune Llc |
Ctla-4 variants
|
|
DK2925350T3
(da)
|
2012-12-03 |
2019-05-13 |
Bristol Myers Squibb Co |
Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
|
|
US9327014B2
(en)
|
2012-12-04 |
2016-05-03 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
MX2015011670A
(es)
|
2013-03-15 |
2016-03-31 |
Biogen Ma Inc |
Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
|
|
KR102320189B1
(ko)
|
2013-04-23 |
2021-11-03 |
엘라스모겐 리미티드 |
특이적 결합 분자의 합성 라이브러리
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
WO2014207748A1
(en)
|
2013-06-27 |
2014-12-31 |
Alexander Biro |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
KR20170032373A
(ko)
|
2014-07-15 |
2017-03-22 |
이뮨 디자인 코포레이션 |
Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
|
|
JP6895374B2
(ja)
|
2014-07-16 |
2021-06-30 |
トランジェーヌＴｒａｎｓｇｅｎｅ |
免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
|
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
SG10201901735XA
(en)
|
2014-09-03 |
2019-03-28 |
Bavarian Nordic As |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
AU2015343048A1
(en)
|
2014-11-06 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
CN107708725A
(zh)
|
2015-04-02 |
2018-02-16 |
坎库雷有限公司 |
用于引发免疫应答的剂和组合物
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
US20180221503A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
US20180221508A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
EA201890729A1
(ru)
|
2015-09-14 |
2018-09-28 |
Элпайн Имьюн Сайнс, Инк. |
Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
|
|
US11034765B2
(en)
|
2015-10-02 |
2021-06-15 |
Symphogen A/S |
Anti-PD-1 antibodies and compositions
|
|
US11684656B2
(en)
|
2015-11-04 |
2023-06-27 |
Taipei Veterans General Hospital |
Combination therapy for malignant diseases
|
|
TW202208440A
(zh)
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
CA3022331A1
(en)
|
2016-05-18 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
AU2020257238A1
(en)
|
2019-04-17 |
2021-12-02 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
|